Skip to main content

NEW YORK (

TheStreet

) --

CHANGE IN RATINGS

Cubist Pharmaceuticals

(CBST)

rated new Buy at Goldman. Stock also placed on the Conviction List. $54 price target. CXA will likely be the company's next big growth driver.

CVS Caremark

(CVS) - Get CVS Health Corporation Report

upgraded at BMO from Market Perform to Outperform, BMO Capital said. $53 price target. Company should see improved margins and earnings power in the coming quarters.

Dril-Quip

(DRQ) - Get Dril-Quip, Inc. Report

downgraded at BofA/Merrill from Buy to Underperform, Bank of America/Merrill Lynch said. Valuation call, based on a $79 price target.

FirstEnergy

(FE) - Get FirstEnergy Corp. Report

downgraded at UBS to Neutral from Buy, UBS said. $49 price target. Standing aside on opaque outlook.

TheStreet Recommends

First Energy downgraded at BMO from Outperform to Market Perform, BMO Capital said. $48 price target. Management has limited earnings visibility.

Fossil

(FOSL) - Get Fossil Group, Inc. Report

downgraded at Citigroup to Neutral from Buy, Citigroup said. $100 price target. Valuation call after rally on quarterly results.

Groupon

(GRPN) - Get Groupon, Inc. Report

downgraded at Sterne Agee from Buy to Neutral, Sterne Agee said. Estimates also cut, as growth appears to be slowing.

Halliburton

(HAL) - Get Halliburton Company Report

upgraded to buy at TheStreet Ratings.

Jive Software

(JIVE)

downgraded at Citigroup to Neutral from Buy, Citigroup said. $21 price target. Thesis not playing out as fast as we'd hoped.

Jack Henry

(JKHY) - Get Jack Henry & Associates, Inc. Report

upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Company has a strong balance sheet and the spending environment is improving.

MGE Energy

(MGEE) - Get MGE Energy, Inc. Report

upgraded at DA Davidson from Underperform to Neutral, DA Davidson said. Valuation call, based on a $48.50 price target.

MGM

(MGM) - Get MGM Resorts International Report

downgraded to sell at TheStreet Ratings.

VeriFone

(PAY)

downgraded at UBS to Neutral from Buy, UBS said. $41 price target. Catalysts played out.

Par Pharmaceutical

( PRX) downgrade at UBS to Neutral from Buy, UBS said. $58 price target. Valuation call given current TPG offer price.

Rackspace

(RAX)

upgraded at Pacific Crest to Outperform, Pacific Crest said. $62 price target. Company is realizing higher margins.

Sapient

(SAPE)

downgraded at Wells from Outperform to Market Perform, Wells Fargo said. Company is seeing slower growth in its Nitro segment.

Vectren

(VVC)

rated new Buy at Brean. $36 price target. Company has a solid yield and can deliver consistent growth over the long term.

Windstream

(WIN) - Get Windstream Holdings, Inc. Report

downgraded at Nomura from Neutral to Reduce, Nomura said. $8.50 price target. Company is leveraged to macro risks and could face increased competition.

STOCK COMMENTS / EPS CHANGES

Jazz Pharmaceuticals

(JAZZ) - Get Jazz Pharmaceuticals Public Limited Company Report

numbers increased at Lazard. JAZZ estimates were raised through 2013, Lazard said. Company is growing across the board and boosted guidance. Buy rating and new $76 price target.

MGM Resorts

(MGM) - Get MGM Resorts International Report

numbers cut at Topeka.Shares of MGM now seen reaching $16, according to Topeka Capital. Estimates also reduced, given slower expected growth in Las Vegas.

Priceline.com

(PCLN)

numbers lowered at Citigroup. Shares of PCLN now seen reaching $740, Citigroup said. Estimates also lowered on lower 3Q guide. Buy rating.

Priceline.com estimates, target cut at Benchmark.PCLN estimates were reduced through 2013, Benchmark said. Company is realizing decelerating growth. Buy rating and new $725 price target.

>To submit a news tip, email:

tips@thestreet.com

.

READERS ALSO LIKE:

>>Rackspace, Priceline, Sirius: Tech Premarket

>>Stock Futures Tilt Lower

Follow

TheStreet

on

Twitter

and become a fan on

Facebook.

This article was written by a staff member of TheStreet.